Clinics and Practice, Volume 14, Issue 1
2024 February - 28 articles
Cover Story: Tuberculosis (TB), a highly infectious airborne disease caused by Mycobacterium tuberculosis (Mtb), currently ranks amongst the top three threats to global health. Therapies capitalizing on the dynamic nature of the human microbiome offer alternative TB treatment options. This review discusses the influence of the human microbiome on immunity as well as the disturbances of gut and lung bacterial compositions due to Mtb infection, resulting in dysbiosis. Because of the microbiome’s role in inflammatory pathways and production of metabolites like short-chain fatty acids, dysbiosis may compromise the host immune system. Additionally, evidence suggests antibiotic treatments and previous Mtb infection may result in increased Mtb susceptibility that can be attributed to microbial profile alterations. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.